Doxorubicin (DOX) is one of the most generally used chemotherapeutic drugs in antitumor applications.However,the severe side effect of DOX to normal tissues limits its dosage in treatment and reduces its curative effect in the clinic.Therefore,developing targeted carriers to deliver DOX specifically to cancer cells is a major task in rumor treatment.Asialoglycoprotein receptors (ASGPR) are considered as a promising target for liver cancer cells,since they are present on the surface of hepatocarcinoma cells with a high density and can facilitate efficient intracellular uptake of the galactose ligand-modified conjugates via receptor-mediated endocytosis [1].